The AI-designed drug pipeline has grown to more than 170 in clinical development today, with 15-20 expected to reach pivotal trials this year. 

AI doesn’t have to improve clinical success rates for a bull case to play out in the AI-aligned biotechs. If it makes shots on goal cheaper by reducing the time and cost of identifying a preclinical target, then